Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Bortezomib in Relapsed/Refractory B-Cell Lymphoma
NCT00038571Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2002
- Primary completion
- Mar 2005
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in B cell lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Started May 2002; status: completed.
02
Drugs
bortezomib
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT00038571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038571.